EPIS® Právní systém | Plné znění

XXXXXXXX KOMISE X XXXXXXXXX PRAVOMOCI (XX) 2020/1182

xx dne 19. xxxxxx 2020,

xxxxxx xx xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxxx xxxxxxx mění xxxx 3 xxxxxxx XX xxxxxxxx Evropského xxxxxxxxxx x Rady (XX) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx x xxxxxx látek x xxxxx

(Xxxx x významem xxx XXX)

XXXXXXXX KOMISE,

s xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,

x ohledem xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx a xxxxxx xxxxx a směsí, x xxxxx x xxxxxxx směrnic 67/548/EHS x 1999/45/ES x x změně nařízení (XX) x. 1907/2006&xxxx;(1), x zejména xx xx. 37 odst. 5 xxxxxxxxx xxxxxxxx,

xxxxxxxx x těmto důvodům:

(1)	Tabulka 3 x části 3 xxxxxxx VI xxxxxxxx (XX) č. 1272/2008 obsahuje seznam xxxxxxxxxxxxxxx klasifikací x xxxxxxxx xxxxxxxxxxxx látek xx základě kritérií xxxxxxxxxxx v xxxxxxx 2 až 5 xxxxxxx X xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx agentuře xxx xxxxxxxx xxxxx („xxxxxxxx“) xxxx x souladu x xxxxxxx 37 xxxxxxxx (XX) x. 1272/2008 xxxxxxxxxx návrhy xx xxxxxxxx harmonizované xxxxxxxxxxx a xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxx xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx některých xxxxxx xxxxx. Xx základě xxxxxxxxxx&xxxx;(2) x xxxxx xxxxxxx, které vydal Xxxxx xxx xxxxxxxxxx xxxxx („XXX“) xxxxxxxx, xxxxx i xxxxxxxxxx xxxxxxxxxxxx xxxxx, xx xxxxxx xxxxxx, xxxxxxxxxxxx xx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x označení xxxxxxxxx xxxxx. Uvedená xxxxxxxxxx xxxxxx XXX xxxx:

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx xxxxxxx... %[X ≤ 70 %],

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxx x xxxxxxx xxxxxxx (x xxxxxxx &xx; 3 μx,xxxxx &xx; 5 μx x xxxxxx xxxxx ≥ 3:1),

—	stanovisko xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně tris(2-methoxyethoxy)vinylsilanu, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—	xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx granulované xxxx,

—	xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxx (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Cu-HDO],

—	stanovisko xx xxx 14. xxxx 2018 xxxxxxx dioktyltin-dilaurátu, [1] stannanu, dioktyl-, xxx(xxxx xxxxxxx) xxxxxxxx [2],

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—	xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (XXX), (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanolu,

—	stanovisko xx dne 8. xxxxxx 2018 ohledně xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—	xxxxxxxxxx ze xxx 8. xxxxxx 2018 ohledně paklobutrazolu (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—	xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2E)-3,7-dimethylokta-2,6-dien-1-olu,

—	stanovisko xx xxx 28. xxxxx 2019 xxxxxxx 2-(4-terc-butylbenzyl)propionaldehydu,

—	stanovisko xx dne 9. xxxxxx 2018 ohledně XXXX-xxxxxxxxxx (XXX), X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, S-ethyl 4-chlor-o-tolyloxythioacetátu,

—	stanovisko xx dne 9. xxxxxx 2018 ohledně xxxxxxxxxx-xxxxxxx,

—	xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), methyl 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx L-(+)-mléčné xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,

—	xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—	xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx xxxxxxxxxx xxxxxxxx …%,

—	xxxxxxxxxx xx dne 14. září 2018 xxxxxxx natrium-N-(hydroxymethyl)glycinátu, [xxxxxxxxxxx xxxxxxxx z xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—	xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 ohledně (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [X-XXX],

—	xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—	xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx (2RS)-2-[4-(4-chlorfenoxy)-2(trifluoromethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-olu, mefentriflukonazolu,

—	stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—	xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (T-4)-bis[1-(hydroxy-kappa-O)pyridin-2(1H)-thionát-kappa-S]zinku,

—	stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-chlor-4-(chlormethyl)-1-[3-trifluormethyl)fenyl]pyrrolidin-2-onu, xxxxxxxxxxxxxxx (XXX),

—	xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 ohledně 4,5-dichlor-2-oktyl-2H-isothiazol-3-onu, [XXXXX],

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [XXXX],

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—	xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [XXX],

—	xxxxxxxxxx xx xxx 15. xxxxx 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx iprovalikarbu (XXX), xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx uhličitým],

—	stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx …%[C> 70 %],

—	xxxxxxxxxx z 9. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—	xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx pirimifos-methylu (XXX), X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx,

—	xxxxxxxxxx xx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,

—	xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—	xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx olova,

—	stanovisko xx xxx 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—	xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—	xxxxxxxxxx ze dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx azoxystrobinu (XXX), methyl (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl-methansulfonátu,

—	stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—	xxxxxxxxxx xx dne 14. září 2018 xxxxxxx xxxxxxxxxx (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—	xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx xxxxxxxxxx (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx hexythiazoxu (XXX), xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxxx,

—	xxxxxxxxxx ze xxx 9. března 2018 xxxxxxx xxxxxxxxxxx (XXX), (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethylen-amino)-1,2,4-triazin-3(2H)-onu,

—	stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), reakční xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxxx,

—	xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx-xxxxx, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx hexyl 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, hexyl 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x látku xxxxx (xxxxx CAS 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (xxxxx x xxxxxx; [xxxxxx xxxxxx &xx; 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [xxxxxx xxxxxx ≥ 1 xx];)), XXX xx xxxx stanovisku xx xxx 30. listopadu 2018 navrhl použít xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx celistvou i xxxxxxxxx xxxxx. Xxxxx xxxxxxxx x nižší xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxx struktuře xxxxx, ke xxxxxxxxxx xxxxxxx xxxxxx prášku x xxxxxxxx x xxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxx forem jiných xxxx x existujících xxxxxxxxx x příloze XX xxxx XXX xxxxxxx další xxxxxxxxx xxxx, xxx má xxx xx celistvou x xxxxxxxxx xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx klasifikace. Xxxxx xxxx byly xxxxxxxxxx xxxx vědecké xxxxxxxx, x xxxxx xxxxxxx, xx xxxxxxxxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx xxxxx, xxx xx xxxxxxxxxx xxxxxxxxxx xxxxxx XXX, xxxxxx xxx vhodná. Xxxxxxxxxxxxxxx xxxxxxxxxxx pro xxxxxxxxx xxxxx proto xxxxxx zařazena do xxxxxxx VI nařízení (XX) č. 1272/2008, xxxxx RAC xxxxxx xxx možnost předložit xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x xxxxx 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx CAS 111-76-2), pro xxxxx xxxxxxxxxxxxx „xxxxxx xxxxxxxx (xxxxxxxxx)“ xxxx xxxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx xxxxxxx vyplývá, xx xxxxxxxxxxx xxx xxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxxxx ve xxxxxxxxxx xxxxxx RAC, xxx xx xxxxxxx xx xxxxxxxx xxxxxxx, xxxxxx xxx xxxxxx. Xxxx xxxxx xxxxxxxxxxxxx xx xxxxx neměla být x xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 xxxxxxx, xxxxx XXX nebude xxx xxxxxxx xxxxxxxxx x xxxxx xxxxx informacím xxxxxxxxxx stanovisko; xxxxxxx xxxxxxx třídy xxxxxxxxxxxxx, x xxxxxxx pojednává xxxxxxxxxx xxxxxx RAC, xx xxxxxxxx xxx xxxx.

(5)	Xxxxxxxx (ES) č. 1272/2008 xx xxxxx xxxx xxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxx xxx, x xxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxx ihned, jelikož xxxxxxxxxx xxxxxxxxx xxxxxxx xxxx xx xx, xxx xxxxxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx x xxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxxxxxx x xxxxxxx xxxxxxxxx xxxxxx. Tato doba xx rovněž xxxxxxxx x xxxx, xxx xxxxxxxxxx xxxx xxxxxxxx xxxx xxxxxxxx opatření xxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx požadavků, xxxxx xxxxxxxx x xxxxxxxx xxxx provedených podle xxxxxx xxxxxxxx. Xxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx x xx. 22 xxxx. 1 xxxx. f) xxxxxxxx Evropského xxxxxxxxxx x Xxxx (ES) x. 1907/2006&xxxx;(3) xxxx xxxxxxxxx stanovené x xxxxxx 50 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 528/2012&xxxx;(4).

(7)	Xxxxxxxxxxx xx však xxxx být umožněno, xxx xxxxx xxxx xxxxxxxxxx xxxxxxxx se xxxxxxxxxxx, označování x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxxxxxxxxxx xxxxxx xxxxxxxx. To xx x xxxxxxx x xxxxxxxxx podle xx. 61 xxxx. 2 xxxxxxxx (XX) x. 1272/2008,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx 1

Xxxxx xxxxxxxx (XX) x. 1272/2008

Tabulka 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xx mění x xxxxxxx s xxxxxxxx xxxxxx xxxxxxxx.

Xxxxxx 2

Xxxxx x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx v xxxxxxxx dvacátým xxxx xx xxxxxxxxx x Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.

Xxxxxxx xx ode xxx 1. března 2022.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx článku xxxxx být látky x směsi xxxxxxxxxxxxx, xxxxxxxxxx x baleny x xxxxxxx x xxxxxxxxx (XX) x. 1272/2008 xx xxxxx xxxxxx xxxxxxxx ještě xxxxx xxxx 1. xxxxxx 2022.

Toto xxxxxxxx xx xxxxxxx x xxxxx xxxxxxx x přímo xxxxxxxxxx xx všech xxxxxxxxx xxxxxxx.

X Bruselu xxx 19. května 2020.

Xx Xxxxxx

Xxxxxx XXX XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx jsou xxxxxxxx na xxxx xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 1907/2006 xx dne 18. xxxxxxxx 2006

o xxxxxxxxxx, xxxxxxxxx, povolování x xxxxxxxxx chemických xxxxx, x zřízení Xxxxxxxx agentury pro xxxxxxxx xxxxx, o xxxxx směrnice 1999/45/XX x o xxxxxxx xxxxxxxx Xxxx (EHS) x. 793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/XXX, 93/67/EHS, 93/105/XX x 2000/21/XX (Xx. xxxx. L 396, 30.12.2006, s. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Evropského parlamentu x Xxxx (XX) x. 528/2012 xx xxx 22. května 2012

x xxxxxxxx xxxxxxxxxx xxxxxxxxx xx trh x xxxxxx xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, s. 1).

PŘÍLOHA

V příloze VI xxxxxxxx (XX) č. 1272/2008 se xxxxxxx 3 x části 3 xxxx xxxxx:

Xxxxxxxx xx xxxx položky:

Indexové xxxxx	Xxxxxxxx název	Číslo XX	Xxxxx XXX	Xxxxxxxxxxx		Xxxxxxxx			Xxxxxxxxxx koncent. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX	Xxxxxxxx
Indexové xxxxx	Xxxxxxxx název	Číslo XX	Xxxxx XXX	Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx	Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx	Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx	Xxxx standardních xxx x xxxxxxxxxxxxx	Xxxx xxxxx. xxxxxxxxxxxx vět x xxxxxxxxxxxxx	Xxxxxxxxxx koncent. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX	Xxxxxxxx
„007-030-00-3	xxxxxxxx dusičná …% [X ≤ 70 %]	231-714-2	7697-37-2.	Ox. Xxx. 3 Xxxxx Xxx. 3 Xxxx Xxxx. 1 A	H272 H331 H314	GHS03 GHS06 GHS05 Dgr	H272 H331 H314	EUH071	Ox. Xxx. 3; X272: X ≥ 65 % xxxxxxxxx: ATE = 2,65 mg/l (páry) Skin Xxxx. 1 A; X314: X ≥ 20 % Xxxx Corr. 1X; X314: 5 % ≤ X &xx; 20 %	B“
„014-048-00-5	vlákna x karbidu křemíku (x xxxxxxx &xx; 3 μm, délce &xx; 5 μx x x xxxxxxx xxxxx ≥ 3:1)	206-991-8	409-21-2 308076-74-6	Xxxx. 1X	X350x	XXX08 Xxx	X350x“
„014-049-00-0	xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx	220-449-8	2768-02-7	Xxxx Xxxx. 1X	X317	XXX07 Xxx	X317“
„014-050-00-6	xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx; 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx	213-934-0	1067-53-4	Xxxx. 1X	X360XX	XXX08 Xxx	X360XX“
„016-098-00-3	xxxxxxxx-xxxxxxxx	210-871-0	624-92-0	Xxxx. Xxx. 2 Xxxxx Tox. 3 Xxxxx Xxx. 3 XXXX SE 3 XXXX XX 1 Eye Xxxxx. 2 Skin Xxxx. 1 Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1	X225 X331 X301 X336 X370 (horní xxxxxxx cesty, xxxxxxxxx) X319 X317 X400 X410	XXX02 XXX06 XXX08 XXX09 Xxx	X225 X331 X301 X336 X370 (xxxxx dýchací xxxxx, xxxxxxxxx) X319 X317 X410		xxxxxxxxx: ATE = 5 xx/x (páry) orální: XXX = 190 xx/xx XX X = 1 X = 10“
„029-024-00-X	xxxxxxxxxxx xxx; [xxxxx xxxxxx: xx 0,9 xx x xx 6,0 xx; xxxxx částic: xx 0,494 xx 0,949 xx]	231-159-6	7440-50-8	Xxxxxxx Xxxxxxx 2	H411	GHS09	H411“
„029-025-00-5	bis(N-hydroxy-N-nitrosocyklohexylaminato-O,O’)měď; bis(N-cyklohexyl-diazenium-dioxy)-měď; [Cu-HDO]	239-703-4	312600-89-8 15627-09-5	Flam. Xxx. 1 Acute Xxx. 4 XXXX RE 2 Xxx Xxx. 1 Aquatic Xxxxx 1 Xxxxxxx Xxxxxxx 1	X228 X302 X373 (xxxxx) X318 X400 X410	XXX02 XXX07 XXX08 XXX05 XXX09 Xxx	X228 X302 X373 (xxxxx) X318 X410		xxxxxx: ATE = 360 xx/xx XX X = 1 M = 1“
„050-031-00-9	xxxxxxxxxx-xxxxxxxx; [1] xxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2]	222-883-3 [1] 293-901-5 [2]	3648-18-8 [1] 91648-39-4 [2]	Xxxx. 1X XXXX XX 1	X360X X372 (xxxxxxxx xxxxxx)	XXX08 Xxx	X360X X372 (xxxxxxxx xxxxxx)“
„601-092-00-0	xxxxxxx[xxx,x]xxxxxxx; xxxxxxx[x,x]xxxxx	205-886-4	191-30-0	Xxxx. 1X Xxxx. 2	H350 H341	GHS08 Dgr	H350 H341		Carc. 1X; X350: X ≥ 0,001 %“
„603-237-00-3	xxxxxxxxx (XXX); (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx	–	125225-28-7 115850-69-6 115937-89-8	Xxxx. 1X Xxxxx Xxx. 4 STOT XX 2 Xxxxxxx Xxxxxxx 1	X360X X302 X373 (xxx, xxxx, xxxxx) X410	XXX08 XXX07 XXX09 Xxx	X360X X302 X373 (xxx, xxxx, xxxxx) X410		xxxxxx: XXX = 500 mg/kg XX X = 100“
„603-238-00-9	xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx	205-594-7	143-24-8	Xxxx. 1X	X360XX	XXX08 Xxx	X360XX“
„603-239-00-4	xxxxxxxxxxxxx (XXX); (2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx	–	76738-62-0	Xxxx. 2 Acute Xxx. 4 Acute Tox. 4 Xxx Irrit. 2 Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1	X361x X332 X302 X319 X400 X410	XXX08 XXX07 XXX09 Xxx	X361x X332 X302 X319 X410		xxxxxxxxx: XXX = 3,13 xx/x (xxxxx xxxx xxxx) xxxxxx: XXX = 490 xx/xx XX X = 10 X = 10“
„603-240-00-X	2,2-bis(brommethyl)propan-1,3-diol	221-967-7	3296-90-0	Carc. 1X Xxxx. 1X	X350 X340	XXX08 Xxx	X350 X340“
„603-241-00-5	xxxxxxxx; (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx	203-377-1	106-24-1	Xxxx Sens. 1	X317	XXX07 Xxx	X317“
„605-041-00-3	2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx	201-289-8	80-54-6	Xxxx. 1X	X360Xx	XXX08 Xxx	X360Xx“
„607-738-00-8	XXXX-xxxxxxxxx (ISO); S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-chlor-o-tolyloxythioacetát	246-831-4	25319-90-8	Acute Xxx. 4 XXXX RE. 2 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X302 X373 (xxxxx) X400 X410	XXX07 XXX08 XXX09 Xxx	X302 X373 (xxxxx) X410		xxxxxx: XXX = 450 mg/kg XX X = 10 X = 10“
„607-740-00-9	xxxxxxxxxx-xxxxxx	248-523-5	27554-26-3	Xxxx. 1B	H360FD	GHS08 Dgr	H360FD“
„607-741-00-4	4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on; xxxxxxxxxxxxxx	–	951659-40-8	Xxxxx Xxx. 4 XXXX RE 2 Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1	X302 X373 (xxxxxxxxx) X400 X410	XXX07 XXX08 XXX09 Xxx	X302 X373 (xxxxxxxxx) X410		xxxxxx: ATE = 500 mg/kg XX X = 10 M = 10“
„607-742-00-X	xxxxxxxxxxxxx-xxxxxx (XXX); xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx	–	317815-83-1	Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1	X400 X410	XXX09 Xxx	X410		X = 1000 X = 1000“
„607-743-00-5	X-(+)-xxxxxx xxxxxxxx; (2 S)-2-hydroxypropanová xxxxxxxx	201-196-2	79-33-4	Xxxx Xxxx. 1X Xxx Xxx. 1	H314 H318	GHS05 Dgr	H314	EUH071“
„607-744-00-0	2-methoxyethylakrylát	221-499-3	3121-61-7	Flam. Xxx. 3 Xxxx. 2 Repr. 1X Xxxxx Xxx. 3 Acute Xxx. 4 Xxxx Xxxx. 1X Xxx Xxx. 1 Xxxx Sens. 1	X226 X341 X360XX X331 X302 X314 X318 X317	XXX02 XXX05 XXX06 XXX08 Xxx	X226 X341 X360XX X331 X302 X314 X317	XXX071	xxxxxxxxx: XXX = 2,7 xx/x (xxxx) xxxxxx: XXX = 404 xx/xx TH“
„607-745-00-6	glyoxylová xxxxxxxx …%	206-058-5	298-12-4	Xxx Dam. 1 Xxxx Xxxx. 1X	X318 X317	XXX05 XXX07 Xxx	X318 X317			X“
„607-746-00-1	xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx; [xxxxxxxxxxx xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]	274-357-8	70161-44-3	Xxxx. 1X Xxxx. 2 Xxxxx Tox. 4 Acute Xxx. 4 STOT XX 3 Xxxx Xxxxx. 2 Xxx Xxxxx. 2 Xxxx Xxxx. 1	X350 X341 X332 X302 X335 X315 X319 X317	XXX08 XXX07 Xxx	X350 X341 X332 X302 X335 X315 X319 X317		xxxxxxxxx: XXX = 3 xx/x (xxxxx xxxx xxxx) xxxxxx: XXX = 1&xxxx;100 xx/xx XX	8 9“
„611-181-00-6	(xxxxx-XXX-xxxxx)xxxxxxxxxx draselný; cyklohexylhydroxydiazen-1-oxid, xxxxxxxx xxx; [X-XXX]	–	66603-10-9	Xxxx. Sol. 1 Xxxxx Xxx. 3 STOT XX 2 Xxxx Xxxxx. 2 Xxx Xxx. 1 Xxxxxxx Xxxxxxx 2	X228 X301 X373 (játra) H315 H318 H411	GHS02 GHS06 GHS08 GHS05 GHS09 Dgr	H228 H301 H373 (xxxxx) X315 X318 X411		xxxxxx: XXX = 136 xx/xx XX“
„612-294-00-3	xxxxxxxxxxxxxxxxxxxxx; X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx; xxxxxxxxxxx-xxxxx-xxxxxx; [XXX]	221-106-5	3006-10-8	Xxxx Corr. 1 Xxx Xxx. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X314 X318 X400 X410	XXX05 XXX09 Xxx	X314 X410	XXX071	X = 100 M = 1&xxxx;000 “
„613-331-00-6	(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx; xxxxxxxxxxxxxxxxxx	–	1417782-03-6	Xxxx Xxxx. 1 Aquatic Xxxxx 1 Xxxxxxx Xxxxxxx 1	X317 X400 X410	XXX07 XXX09 Xxx	X317 X410		X = 1 X = 1“
„613-332-00-1	xxxxxxxxxxxxxxx (ISO); 1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluormethyl)-1H-pyrazol-1-yl]ethanon	–	1003318-67-9	Aquatic Xxxxxxx 1	X410	XXX09 Xxx	X410		X = 1“
„613-333-00-7	pyrithion-zinek; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx	236-671-3	13463-41-7	Xxxx. 1X Xxxxx Xxx. 2 Xxxxx Xxx. 3 XXXX XX 1 Xxx Xxx. 1 Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1	X360X X330 X301 X372 X318 X400 X410	XXX08 XXX06 XXX05 XXX09 Xxx	X360X X330 X301 X372 X318 X410		xxxxxxxxx: XXX = 0,14 xx/x (xxxxx xxxx mlha) orální: XXX = 221 xx/xx TH M = 1&xxxx;000 X = 10“
„613-334-00-2	xxxxxxxxxxxxxx (XXX); 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx	262-661-3	61213-25-0	Xxxx. 1B Acute Tox. 4 Xxxx Xxxx. 1 Aquatic Xxxxx 1 Aquatic Xxxxxxx 1	X360XX X302 X317 X400 X410	XXX08 XXX07 XXX09 Xxx	X360XX X302 X317 X410		xxxxxx: XXX = 500 xx/xx XX X = 100 X = 100“
„613-335-00-8	4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXXXX]	264-843-8	64359-81-5	Xxxxx Tox. 2 Xxxxx Xxx. 4 Xxxx Xxxx. 1 Eye Xxx. 1 Xxxx Xxxx. 1 X Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X330 X302 X314 X318 X317 X400 X410	XXX06 XXX05 XXX09 Xxx	X330 X302 X314 X317 X410	XXX071	xxxxxxxxx: XXX = 0,16 xx/x (xxxxx xxxx xxxx) xxxxxx: XXX = 567 xx/xx XX Xxxx Xxxxx. 2; X315: 0,025 % ≤ X &xx; 5 % Xxx Xxxxx. 2; X319: 0,025 % ≤ X < 3 % Xxxx Xxxx. 1 X; X317: C ≥ 0,0015 % X = 100 M = 100“
„613-336-00-3	2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx; [XXXX]	–	2527-66-4	Xxxxx Xxx. 4 Acute Xxx. 3 Skin Corr. 1X Xxx Xxx. 1 Xxxx Xxxx. 1 X Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 2	X312 X301 X314 X318 X317 X400 X411	XXX06 XXX05 XXX09 Xxx	X312 X301 X314 X317 X410	XXX071	xxxxxxxx: XXX = 1&xxxx;100 xx/xx TH orální: XXX = 175 xx/xx XX Xxxx Xxxx. 1 A; X317: X ≥ 0,0015 % X = 1“
„616-228-00-4	3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx; xxxxxxxxxxxx	–	907204-31-3	Xxxx. Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X362 X400 X410	XXX09 Xxx	X362 X410		X = 1 M = 1“
„616-230-00-5	N-(hydroxymethyl)akrylamid; xxxxxxxxxxxxxxxxx; [XXX]	213-103-2	924-42-5	Xxxx. 1X Xxxx. 1B STOT XX 1	X350 X340 X372 (xxxxxxxxx xxxxxxx xxxxxx)	XXX08 Xxx	X350 X340 X372 (xxxxxxxxx xxxxxxx xxxxxx)“
„616-231-00-0	5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx; xxxxxxxxx	–	494793-67-8	Xxxx. 2 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	H351 H400 H410	GHS08 GHS09 Wng	H351 H410		M = 1 X = 1“
„616-232-00-6	xxxxxxxxxxxx (XXX); xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx	–	140923-17-7	Xxxx. 2	X351	XXX08 Xxx	X351“
„616-233-00-1	xxxxxxxxxx (XXX); X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx	–	175217-20-6	XXXX XX 2 Aquatic Xxxxxxx 2	X373 X411	XXX08 XXX09 Xxx	X373 X411“
„650-057-00-6	Xxxxxxx, xxxxxxx [xxxx lisovaný za xxxxxxx ze xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, extrahovaný xxxxxxxxxxxxxx xxxxxx xxxxxxxxx]	283-644-7	84696-25-3	Xxxxxxx Xxxxxxx 3	H412		H412“

položky xxxxxxxxxxxx xxxxxxxxx číslům 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X xx xxxxxxxxx xxxxxx položkami:

Indexové xxxxx	Xxxxxxxx xxxxx	Xxxxx ES	Číslo XXX	Xxxxxxxxxxx		Xxxxxxxx			Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx a ATE	Poznámky
Indexové xxxxx	Xxxxxxxx xxxxx	Xxxxx ES	Číslo XXX	Kódy xxxx a xxxxxxxxx xxxxxxxxxxxxx	Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx	Xxxx xxxxxxxxxxx xxxxxxx x signálních xxxx	Xxxx xxxxxxxxxxxx xxx x nebezpečnosti	Kódy doplň. xxxxxxxxxxxx vět o xxxxxxxxxxxxx	Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx a ATE	Poznámky
„007-004-00-1	xxxxxxxx xxxxxxx …% [X &xx; 70 %]	231-714-2	7697-37-2	Xx. Xxx. 2 Acute Xxx. 1 Xxxx Xxxx. 1 A	H272 H330 H314	GHS03 GHS06 GHS05 Dgr	H272 H330 H314	EUH071	Ox. Liq. 2; H272: X ≥ 99 % Xx. Xxx. 3; X272: 70 % ≤ X < 99 %	X“
„014-018-00-1	xxxxxxxxxxxxxxxxxxxxxxxxxxx; [X4]	209-136-7	556-67-2	Xxxx. 2 Xxxxxxx Xxxxxxx 1	X361x *** X410	XXX08 XXX09 Xxx	X361x *** H410		M = 10“
„015-134-00-5	pirimifos-methyl (XXX); X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx	249-528-5	29232-93-7	Xxxxx Xxx. 4 STOT XX 1 Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1	X302 X372 (nervový xxxxxx) X400 X410	XXX07 XXX08 XXX09 Xxx	X302 X372 (xxxxxxx xxxxxx) X410		xxxxxx: XXX = 1 414 xx/xx TH M = 1&xxxx;000 X = 1 000 “
„015-181-00-1	xxxxxx	232-260-8	7803-51-2	Xxxx. Gas 1 Xxxxx. Xxx Xxxxx Xxx. 1 Xxxx Xxxx. 1X Xxxxxxx Xxxxx 1	X220 X330 X314 X400	XXX02 XXX04 XXX06 XXX05 XXX09 Xxx	X220 X330 X314 X400		xxxxxxxxx: XXX = 10 xxxX (xxxxx)	X“
„050-021-00-4	xxxxxxxxxxxxxxxxxxxxx	222-583-2	3542-36-7	Xxxx. 1X Xxxxx Xxx. 2 XXXX XX 1 Xxxxxxx Xxxxxxx 3	H360D H330 H372 ** X412	XXX08 XXX06 Xxx	X360X X330 X372 ** X412		Xxxx. 1X; X360 X: C ≥ 0,03 % inhalační: XXX = 0.098 xx/X (prach xxxx xxxx)“
„050-027-00-7	2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [XXXX]	239-622-4	15571-58-1	Xxxx. 1X XXXX XX 1 Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1	X360X X372 (xxxxxxxx xxxxxx) X400 X410	XXX08 XXX09 Xxx	X360X X372 (xxxxxxxx systém) H410“
„082-013-00-1	olověný xxxxxx; [xxxxxx xxxxxx &xx; 1 xx]	231-100-4	7439-92-1	Xxxx. 1 X Xxxx. Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	H360FD H362 H400 H410	GHS08 GHS09 Dgr	H360FD H362 H410		Repr. 1 X; X360X: X ≥ 0,03 % X = 1 X = 10“
„603-014-00-0	2-xxxxxxxxxxx-1-xx; xxxxxxxxxxxxxxxxxxxxxxxxxxxx	203-905-0	111-76-2	Xxxxx Tox. 4* Xxxxx Xxx. 4 Skin Xxxxx. 2 Xxx Xxxxx. 2	X332 X302 X315 X319	XXX07 Xxx	X332 X302 X315 X319		xxxxxx: XXX = 1&xxxx;200 mg/kg XX“
„603-065-00-9	x-xxx(2,3-xxxxxxxxxxxx)xxxxxx; xxxxxxxxxxxxxxxxxxxxxxxxx	202-987-5	101-90-6	Xxxx. 1X Xxxx. 2 Xxxxx Tox. 3 Xxxxx Tox. 4 Xxxx Xxxxx. 2 Xxx Irrit. 2 Xxxx Sens. 1 Aquatic Xxxxxxx 3	X350 X341 X311 X302 X315 X319 X317 X412	XXX08 XXX06 Xxx	X350 X341 X311 X302 X315 X319 X317 X412		xxxxxxxx: ATE = 300 xx/xx XX xxxxxx: ATE = 500 mg/kg XX“
„607-177-00-9	xxxxxxxxxx-xxxxxx (XXX); xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx	401-190-1	101200-48-0	XXXX XX 2 Xxxx Xxxx. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X373 X317 X400 X410	XXX08 XXX07 XXX09 Xxx	X373 X317 X410		X = 100 X = 100“
„607-256-00-8	xxxxxxxxxxxx (XXX); xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx	–	131860-33-8	Xxxxx Xxx. 3 Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1	X331 X400 X410	XXX06 XXX09 Xxx	X331 X410		xxxxxxxxx: XXX = 0,7 xx/x (xxxxx xxxx xxxx) X = 10 X = 10“
„607-314-00-2	xxxxxxxxxxx (XXX); (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx	247-525-3	26225-79-6	Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X400 X410	XXX09 Xxx	X410		X = 1 X = 1“
„609-041-00-4	2,4-dinitrofenol	200-087-7	51-28-5	Acute Xxx. 3 * Xxxxx Xxx. 3 Acute Tox. 2 XXXX RE 1 Xxxxxxx Xxxxx 1	H331 H311 H300 H372 H400	GHS06 GHS08 GHS09 Dgr	H331 H311 H300 H372 H400		dermální: XXX = 300 mg/kg XX orální: ATE = 30 mg/kg XX“
„609-064-00-X	xxxxxxxxx (XXX); 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx	–	104206-82-8	Xxxx. 2 STOT XX 2 Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1	H361d H373 (xxx, xxxxxxx xxxxxx) X400 X410	XXX08 XXX09 Xxx	X361x X373 (xxx, xxxxxxx xxxxxx) X410		X = 10 X = 10“
„613-112-00-5	xxxxxxxxxx (XXX); 2-xxxxx-2X-xxxxxxxxxx-3-xx; [OIT]	247-761-7	26530-20-1	Acute Xxx. 2 Acute Tox. 3 Xxxxx Tox. 3 Skin Xxxx. 1 Xxx Xxx. 1 Xxxx Xxxx. 1 X Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X330 X311 X301 X314 X318 X317 X400 X410	XXX06 XXX05 XXX09 Xxx	X330 X311 X301 X314 X317 X410	XXX071	xxxxxxxxx: XXX = 0,27 xx/x (prach nebo xxxx) xxxxxxxx: XXX = 311 xx/xx TH xxxxxx: XXX = 125 xx/xx XX Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 % X = 100 X = 100“
„613-115-00-1	xxxxxxxxx (XXX); 3-xxxxxxx-5-xxxxxxxxxxxxxx	233-000-6	10004-44-1	Xxxx. 2 Acute Xxx. 4 Xxx Xxx. 1 Xxxx Xxxx. 1 Xxxxxxx Chronic 2	X361x X302 X318 X317 X411	XXX08 XXX07 XXX05 XXX09 Xxx	X361x X302 X318 X317 X411		xxxxxx: ATE = 1&xxxx;600 xx/xx XX“
„613-125-00-6	xxxxxxxxxxx (XXX); xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx	–	78587-05-0	Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	H400 H410	GHS09 Wng	H410		M = 1 X = 1“
„613-202-00-4	xxxxxxxxxx (XXX); (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx	–	123312-89-0	Xxxx. 2 Xxxx. 2 Xxxxxxx Xxxxxxx 1	H351 H361fd H410	GHS08 GHS09 Wng	H351 H361fd H410		M = 1“
„613-259-00-5	xxxxxxxxxxx (ISO); reakční xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát	428-790-6	72963-72-5	Carc. 2 Acute Xxx. 4 Xxxxx Tox. 4 XXXX SE 2 Aquatic Xxxxx 1 Xxxxxxx Xxxxxxx 1	X351 X332 X302 X371 (nervový systém; xxxxxx, xxxxxxxxx) X400 X410	XXX08 XXX07 XXX09 Xxx	X351 X332 X302 X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx) X410		xxxxxxxxx: XXX = 1,4 xx/x (xxxxx xxxx xxxx) xxxxxx: ATE = 550 mg/kg XX X = 10 X = 10“
„616-014-00-0	xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, xxxxx(xxxxxx)xxxxxxxxx	202-496-6	96-29-7	Xxxx. 1X Xxxxx Xxx. 4 Acute Xxx. 3 STOT SE 3 XXXX XX 1 XXXX XX 2 Xxxx Xxxxx. 2 Xxx Dam. 1 Xxxx Xxxx. 1	X350 X312 X301 X336 X370 (xxxxx xxxxxxx cesty) H373 (xxxxxx xxxx) X315 X318 X317	XXX08 XXX06 XXX05 Xxx	X350 X312 X301 X336 X370 (horní xxxxxxx xxxxx) X373 (krevní oběh) H315 H318 H317		dermální: XXX = 1 100 xx/xx XX xxxxxx: XXX = 100 xx/xx TH“
„617-006-00-X	bis(α,α-dimethylbenzyl)peroxid	201-279-3	80-43-3	Org. Xxxxx. X Xxxx. 1X Xxxx Irrit. 2 Xxx Xxxxx. 2 Aquatic Xxxxxxx 2	H242 H360D H315 H319 H411	GHS02 GHS08 GHS07 GHS09 Dgr	H242 H360D H315 H319 H411“

3)	položky xxxxxxxxxxxx xxxxxxxxx xxxxxx 601-064-00-8 x 607-693-00-4 xx xxxxxxx.

Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

XXXXXXXX KOMISE X XXXXXXXXX PRAVOMOCI (XX) 2020/1182

xx dne 19. xxxxxx 2020,

xxxxxx xx xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxxx xxxxxxx mění xxxx 3 xxxxxxx XX xxxxxxxx Evropského xxxxxxxxxx x Rady (XX) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx x xxxxxx látek x xxxxx

Xxxxxx 1

Xxxxxx 2

Xxxxx x xxxxxxxx x xxxxxxxxxxxx

PŘÍLOHA

Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu. Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

XXXXXXXX KOMISE X XXXXXXXXX PRAVOMOCI (XX) 2020/1182

xx dne 19. xxxxxx 2020,

xxxxxx xx xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxxx xxxxxxx mění xxxx 3 xxxxxxx XX xxxxxxxx Evropského xxxxxxxxxx x Rady (XX) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx x xxxxxx látek x xxxxx

Xxxxxx 1

Xxxxxx 2

Xxxxx x xxxxxxxx x xxxxxxxxxxxx

PŘÍLOHA

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.